Stockscreener 앱 받기
3.92
1.82%
0.07
시장 영업 전:
3.96
0.04
+1.02%
전일 마감가:
$3.85
열려 있는:
$3.86
하루 거래량:
1.93M
Relative Volume:
0.68
시가총액:
$645.28M
수익:
$296.15M
순이익/손실:
$24.02M
주가수익비율:
32.50
EPS:
0.1206
순현금흐름:
$127.01M
1주 성능:
+9.50%
1개월 성능:
-6.22%
6개월 성능:
+24.05%
1년 성능:
+532.16%
1일 변동 폭
$3.80
$3.93
1주일 범위
$3.42
$3.94
52주 변동 폭
$0.55
$5.78
아이언우드 제약 Stock (IRWD) Company Profile
명칭
Ironwood Pharmaceuticals Inc
전화
617-621-7722
주소
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.92 | 633.76M | 296.15M | 24.02M | 127.01M | 0.1206 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
아이언우드 제약 Stock (IRWD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-04-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | 개시 | Leerink Partners | Market Perform |
| 2024-08-08 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | 개시 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Wells Fargo | Overweight |
| 2023-11-09 | 개시 | Jefferies | Buy |
| 2023-09-28 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-02 | 개시 | CapitalOne | Overweight |
| 2022-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-09-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | 개시 | Northland Capital | Outperform |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-11-07 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-07-23 | 개시 | H.C. Wainwright | Sell |
| 2018-05-09 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2017-07-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2017-05-03 | 개시 | Wells Fargo | Outperform |
| 2017-04-07 | 재확인 | Mizuho | Buy |
| 2017-02-22 | 재확인 | Barclays | Equal Weight |
| 2016-11-04 | 재확인 | Mizuho | Buy |
| 2016-10-24 | 재확인 | Wedbush | Neutral |
| 2016-10-10 | 재확인 | Mizuho | Buy |
| 2016-09-27 | 재확인 | WallachBeth | Hold |
모두보기
아이언우드 제약 주식(IRWD)의 최신 뉴스
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity (NASDAQ:IRWD) - Seeking Alpha
Ironwood Pharmaceuticals (IRWD) sets interim CFO fee and RSU grant - Stock Titan
Ironwood (IRWD) PFO Ronald Silver receives 25,000-share restricted stock grant - Stock Titan
Kyverna Therapeutics appoints Greg Martini as CFO - MSN
Is Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement? - Insider Monkey
Ironwood Pharmaceuticals (IRWD) price target increased by 28.97% to 7.04 - MSN
Ironwood reiterates 2026 LINZESS guidance of $1.125B-$1.175B as STARS-2 initiation nears - MSN
Kyverna Therapeutics Appoints Greg Martini CFO Ahead of Potential Commercial Launch - citybiz
Top Small-Cap Stocks to Watch: Ironwood Pharmaceuticals (IRWD) L - GuruFocus
IRWD News | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Ironwood Pharma drops after CFO transition - MSN
Ironwood Pharmaceuticals: Still A Profitable Opportunity (NASDAQ:IRWD) - Seeking Alpha
Armistice reports 15.03M Ironwood stake (NASDAQ: IRWD) in 13G/A - Stock Titan
Ironwood Pharmaceuticals, Inc.Class A Common Stock (NQ: IRWD - FinancialContent
Renaissance reports 4.90% stake in Ironwood (IRWD) - Stock Titan
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating - Moomoo
Ironwood Pharma Announces CFO Resignation and Interim Successor - The Globe and Mail
Ironwood stock down despite Q1 earnings and revenue beat - MSN
Earnings call transcript: Ironwood’s Q1 2026 earnings beat forecasts, stock dips - Investing.com
Ironwood Pharmaceuticals: CFO Resignation Knocks SharesA Downgrade Is Due (NASDAQ:IRWD) - Seeking Alpha
Ironwood Pharmaceuticals (IRWD) Shares Drop 12% After CFO Resignation Announcement - GuruFocus
Ironwood Pharma stock drops after CFO exit (IRWD:NASDAQ) - Seeking Alpha
Ironwood Pharmaceuticals, Inc. Files Form 8-K with SEC: Company Details and Regulatory Disclosures - Minichart
Ironwood Pharmaceuticals IncGregory Martini resigns as CFO effective May 15, 2026SEC filing - marketscreener.com
[8-K] IRONWOOD PHARMACEUTICALS INC Reports Material Event - Stock Titan
TradingKey - TradingKey
Ironwood Pharmaceuticals stock (US46333X1081): Revenue surge and earnings beat signal turnaround - AD HOC NEWS
Ironwood Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IRWD) 2026-05-11 - Seeking Alpha
Results: Ironwood Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Results: Ironwood Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - 富途牛牛
Ironwood Pharmaceuticals (NASDAQ:IRWD) Downgraded by Wall Street Zen to "Hold" - MarketBeat
Ironwood Stock Down Despite Q1 Earnings and Revenue Beat - sharewise.com
Ironwood Pharmaceuticals Q1 Earnings Call Highlights - sharewise.com
Q1 2026 Ironwood Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Ironwood: Q1 Earnings Snapshot - theheraldreview.com
Ironwood (IRWD) turns loss to profit as LINZESS drives Q1 2026 revenue surge - Stock Titan
아이언우드 제약 (IRWD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.92%
4.44%
자본화:
|
볼륨(24시간):